!-Bing tags ->
<!- End Bing tags ->
Is CINQAIR Right for Your Patient?
CINQAIR offers weight-based dosing for adult patients with
severe asthma and an eosinophilic phenotype 1
Administered by an HCP
CINQAIR is for IV infusion only. Do not administer as IV push or bolus.
HCP administration in each infusion setting helps ensure consistent dosing and administration
The logistics of at-home infusion can be handled by a specialty pharmacy professional engaged through Teva Support Solutions
® Dosing schedule and IV administration enable severe asthmatic patients to have monthly contact with an HCP
IV doses of 3 mg/kg once every 4 weeks
Administered by an HCP in as little as 20-50 minutes*
An option for patients who cannot or do not want to self-inject
Provides visibility to delayed or missed doses
REFERENCES: 1. CINQAIR Prescribing Information. West Chester, PA. Teva Respiratory, LLC. 2. Cyriac JM, James E. Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother. 2014;5(2):83-87. 3. Data on file (clinical study report: a 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of reslizumab [3.0 mg/kg] in the reduction of clinical asthma exacerbations in patients [12-75 years of age] with eosinophilic asthma. Study C38072/3083). Parsippany, NJ. Teva Respiratory, LLC. February 2015.
INDICATIONS AND USAGE
CINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
Limitations of Use: CINQAIR is
not indicated for:
IMPORTANT SAFETY INFORMATION
Anaphylaxis, occurring in 0.3% of CINQAIR patients in clinical studies, was reported as early as the second dose.
As anaphylaxis can be life-threatening, observe patients after CINQAIR administration and be prepared to manage anaphylaxis. Discontinue CINQAIR immediately if there are signs or symptoms of anaphylaxis.
IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS
Acute Asthma Symptoms or Deteriorating Disease: Do not use CINQAIR to treat acute asthma symptoms or exacerbations, acute bronchospasms, or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after CINQAIR initiation.
Malignancy: In clinical studies, 6/1028 (0.6%) of CINQAIR patients had at least 1 malignant neoplasm vs 2/730 (0.3%) of placebo patients. The malignancies were diverse without clustering of any tissue type. Most malignancies were diagnosed within 6 months of CINQAIR use.
Reduction of Corticosteroid Dosage: Reduction of maintenance corticosteroids following use of CINQAIR was not assessed. Do not abruptly discontinue systemic or inhaled corticosteroids upon CINQAIR initiation. Reductions in corticosteroid dose, if appropriate, should be gradual and supervised by a physician and may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroids.
Parasitic (Helminth) Infection: Eosinophils may be involved in immunological response to helminth infections. Treat patients with preexisting helminth infections before initiating CINQAIR. If patients become infected while receiving CINQAIR and do not respond to anti-helminth treatment, discontinue CINQAIR until infection resolves.
. Please see Full Prescribing Information, including Boxed WARNING